The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment
- 1 October 1999
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 107 (1) , 148-153
- https://doi.org/10.1046/j.1365-2141.1999.01676.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.Journal of Clinical Oncology, 1997
- Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanismBiochemical Journal, 1997
- Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factorsPublished by Elsevier ,1996
- Emergence of CD52 −, glycosyiphosphatidylinositol-anchor deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatmentInternational Immunology, 1996
- The dual pathogenesis of paroxysmal nocturnal hemoglobinuriaCurrent Opinion in Hematology, 1996
- Natural History of Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 1995
- Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuriaPublished by Elsevier ,1993
- The Cloning of PIG-A, a Component in the Early Step of GPI-Anchor BiosynthesisScience, 1993
- The CAMPATH‐1 antigen (CDw52)Tissue Antigens, 1990